



# The new leader in lupin-based protein

Investor Presentation | October 2023

FRA: 2WO

# Disclaimer

This presentation has been prepared by Wide Open Agriculture Limited (ASX: WOA) (the "Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

#### **FUTURE MATTERS**

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

#### **US DISCLOSURE**

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 ("Securities Act"). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

# **Acquisition Summary**



## Acquisition

- WOA has purchased the manufacturing assets of Prolupin GmbH
- Acquisition cost A\$4.2m cash
- **Ø** WOA will become the worlds leading lupin protein producer



## Rationale

- Immediate operational footprint in Europe
- Accelerates commercial scale production of Buntine Protein®
- Brings forward global launch of Buntine Protein®



# **Funding**

- Raising approx. A\$6.2m via placement
- Cornerstone investment received of A\$3.5m
- Additional SPP for A\$1.5m



# Demand for plant-based protein is exploding...



Total global plant-based retail market size (USD)<sup>1</sup>



22% of people globally now eat plant-based food<sup>2</sup>



42% of people say we will be eating plant-based food instead of meat in ten years<sup>2</sup>



79% of Millennials and Gen zers already regularly eat plant-based<sup>3</sup>

<sup>(1)</sup> Bloomberg Intelligence, OECD FAO Agricultural Outlook 2021-2030

Grains of Truth 2: EAT - GlobeScan global consumer research on a sustainable food system

<sup>(3)</sup> https://infomineo.com/agriculture/plant-based-food-takeove


# Protein demand is expected to continue

## The world needs more protein

- **Ø** Global population growing by over 80 million per year
- **Ø** We will need to feed 9.7bn people by 2050
- Protein consumption will increase 32% 78% by 2050<sup>1</sup>

## Protein is essential for humans

- Critical nutrient your body needs to function properly
- Helps repairs muscle and improves immune system
- Increasing recognition high-protein diets have benefits for weight loss





# Traditional protein is taking a toll on our planet



### Livestock

- Accounts for 60% of all greenhouse gases from food production<sup>2</sup>
- Heavy land, pollution and water use





## Seafood

- 35% of fish stocks have been fished beyond sustainable limits<sup>3</sup>
- Overfishing is impacting entire ecosystems



## **Current Plant-based**

- Soy production generates greenhouse gases
- Soy also demands high energy, water and resource use

- (1) European Commission Joint Research Centre (JRC) (2) Poore & Nemecek (2018)
- (2) Xu et al 2021 "Global greenhouse gas emissions from animal-based foods are twice those of plant-based foods"
  - United Nations FAO's 2022 State of World Fisheries and Aquaculture (SOFIA) report

# Buntine Protein® is the answer

## Better for the planet

- Breakthrough climate-conscious lupin-based protein
- Lupins play a key role in a grain cropping rotation to restore soil
- Minimal use of water and inputs





### Better for consumers

- Cleanest, most neutral tasting protein on the market
- Suitable for all ages and diets
- Zero harmful substances

## Better nutritional value

- Higher natural protein content than other legumes, including pea and soy
- Low fat and non-GMO
- Low GI and gluten free





## **Better for Industry**


- Neutral flavor and color making it ideal for a broad range of food application
- Superior emulsification solubility and gelation compared to soy and pea- clean label











# **Buntine Protein® Sales Validation**




Strong sales pipeline



+15 ser glo



+150 samples sent to large global food companies



Indicative demand is 400+ tonnes





Entering Prolupin facility with high utilisation



Sales distribution secured for the U.S. & ANZ





1<sup>st</sup> Buntine Protein® product release Q4 CY23






# We can now match demand with production




### **Pilot Production**




## **Kewdale Facility**

- Operational pilot scale production facility located within Dirty Clean Food's production centre
- Primarily used for research and development and supplying samples

5-10tpa










- WOA has signed a non-binding MoU with Saputo Dairy Australia, one of Australia's leading dairy producers
- Saputo will potentially provide WOA the path to large scale commercial production of Buntine Protein®

Potential 5,000tpa



- WOA has completed an agreement to purchase the assets of Prolupin GmbH for A\$4.2m (€2.5m) in cash<sup>2</sup>
- Based in Grimmen, Germany, Prolupin was the market leader in lupin protein isolate production
- The manufacturing facilities of Prolupin have an initial capacity of 500tpa expected to reach 1,000tpa production of Buntine Protein® with modest investment (∼\$3m) within 1-2 years





\$17.6 Million Book Value<sup>1</sup>



- (1) Estimated values only based on conversations with Prolupin.

  Book value represents replacement book value
- (2) Subject to final creditors approval



# **Acquisition Benefits**



European footprint

Immediate operational footprint in Europe and an existing B2B pipeline



**Accelerated production** 

Commercial scale production of Buntine Protein® within six months



Future expansion


Expected positive cashflow to fund future investment and expansion



Experienced team

Experienced team with decades of plant based protein experience

# **Potential Prolupin Asset Economics**



- Significant opportunity to capitalise on strong demand in B2B sales for Buntine Protein®
- Prolupin's facility has the ability to produce lupin fibre as a by product of Buntine Protein® production.
- Potential future lupin fibre sales could provide significant upside on the economics
- Margin upside expected with higher volumes



**Pea Protein** \$9,000 Per Tonne<sup>1</sup>



**Soy Protein** \$10,000 Per Tonne<sup>1</sup>




Buntine Protein® Expected to sell at a premium to pea & soy



# **Catalysts to Drive Value**

Manufacturing:	Q4 CY23	Q1 CY24	Q2 CY24	Q3 CY24	Q4 CY24
Capital raise to acquire Prolupin					 
Final creditor approval of Prolupin sale		 			
Complete Prolupin acquisition					
Begin facility modification to produce Buntine Protein®					
Successful Buntine Protein® produced at the facility					
Facility expansion from 500tpa to 1,000tpa					
Complete Saputo 'Definitive Agreement'					
Sales / corporate:					
Launch initial Buntine Protein® products in Australia					
Initial sales and revenue received from Prolupin's pipeline					
Update on European sales progress					 
Secure additional global sales distribution agreements					
Commercial sales from Prolupin facility					
Update on actively in APAC, USA & Europe					 



# Capital Raising Deal Overview

Current Capital Structure	WOA
Last Price <sup>1</sup>	\$0.33
Shares Outstanding (m)	142.8
Market Capitalisation (m)	\$46.4
2023 Revenue (m)	\$11.5
Cash on Hand (m) <sup>2</sup>	\$5.9
Debt Outstanding (m) <sup>3</sup>	\$0.6

Top Shareholders	Holding	
FANJA PON & HANS RAVE	11.6%	
COMMONLAND FOUNDATION	8.5%	
ANTHONY MASLIN	5.6%	
DR BEN COLE	5.3%	

**WOA to raise A\$6.2m** via an institutional placement for purchase of Prolupin and accelerating BP commercial launch

Plus an SPP for A\$1.5m<sup>4</sup>

**Use of Proceeds:** A\$4.2m purchase price, A\$2.0m for Buntine expansion and drying equipment, \$A1.5m working capital

**Status**: Confirmed cornerstone investment from largest shareholder for over half the \$6.2m placement

Price: A\$0.20c per share (38.5% discount to last close)

**Issuance:** approx. 31 million shares. 142 million shares outstanding.

Post-deal share count: Approx.173 million

<sup>(4)</sup> SPP to be approved at the AGM



<sup>(1) 17&</sup>lt;sup>th</sup> April 2023

<sup>(2)</sup> Cash @ 30 June 2023

<sup>(3)</sup> Debt @ 30 June 2023

# **Executive Summary**

Acquisition of Lupin Protein manufacturing assets	<ul> <li>WOA has purchased the manufacturing assets of Prolupin GmbH at a small fraction of its value.</li> <li>The deal will make WOA the leading producer of lupin protein in the world, and accelerate the commercial scale launch of Buntine Protein®.</li> <li>The site is capable of producing 500 tpa of lupin protein now with fast expansion to 1,000 tpa</li> <li>Assets include:         <ul> <li>State of the art manufacturing facility</li> <li>Software assets and technical infrastructure</li> <li>7 patent families related to lupin protein</li> <li>A current B2B pipeline of over 100 tonnes</li> </ul> </li> </ul>
Acquisition Consideration	<ul> <li>A\$4.2m (€2.5m) in cash</li> <li>Total replacement asset value acquired approx. A\$17m (€11m); previous company valuation A\$88m (€55m)</li> <li>Purchase price is estimated to be 1/6 of the cost for WOA to build a dedicated facility with the same capacity</li> </ul>
Strategic Rationale	<ul> <li>The deal is expected to remove the capital hurdle to profitable lupin protein production</li> <li>Immediate operational footprint in Europe with advanced manufacturing infrastructure</li> <li>Accelerates commercial scale production and global launch of Buntine Protein®</li> <li>Expected positive cashflow to fund future investment and expansion of facility</li> </ul>
Acquisition Funding	<ul> <li>WOA to raise approximately A\$6.2m via a placement for purchase of Prolupin and accelerating Buntine Protein® commercial launch</li> <li>Confirmed cornerstone investment from largest shareholder for over half of the \$6.2m placement</li> <li>Plus an SPP for A\$1.5m<sup>1</sup></li> </ul>



# Thank You.

## Jay Albany

Chief Executive Officer
M: (+61) 0434 473 047
E: jay@wideopenagriculture.com.au

## **Matthew Skinner**

Chief Financial Officer M: (+61) 0468 303 620 E: matthew.s@wideopenagriculture.com.au

